MARKET

THAR

THAR

Tharimmune Inc
NASDAQ
3.380
+0.350
+11.55%
After Hours: 3.380 0 0.00% 19:29 01/02 EST
OPEN
3.190
PREV CLOSE
3.030
HIGH
3.560
LOW
3.150
VOLUME
1.11M
TURNOVER
--
52 WEEK HIGH
9.08
52 WEEK LOW
0.9520
MARKET CAP
118.45M
P/E (TTM)
-0.8226
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 2d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 12/29/2025 21:05
Weekly Report: what happened at THAR last week (1222-1226)?
Weekly Report · 12/29/2025 09:13
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 12/22/2025 12:05
Why Clearwater Analytics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Benzinga · 12/22/2025 11:00
Weekly Report: what happened at THAR last week (1215-1219)?
Weekly Report · 12/22/2025 09:13
Tharimmune Raises $545 Million in Private Placement
Reuters · 12/18/2025 13:15
Tharimmune Inc. Announces Date for Upcoming Special Stockholders Meeting
Reuters · 12/16/2025 21:21
More
About THAR
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.

Webull offers Tharimmune Inc stock information, including NASDAQ: THAR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THAR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading THAR stock methods without spending real money on the virtual paper trading platform.